Applications of 1-[2-Amino-1-(4-Methoxyphenyl)-Ethyl]-Cyclohexanol Hydrochloride in Industrial Manufacturing

1-[2-Amino-1-(4-Methoxyphenyl)-Ethyl]-Cyclohexanol Hydrochloride serves as a specialty intermediate in several regulated industries, where controlled synthesis and precision formulation drive end-product quality and compliance. Drawing from our manufacturer experience, we supply this compound to a focused range of industrial sectors with clearly defined standards, process requirements, and established downstream markets. Below we outline its adopted applications across core production fields.

1. Active Pharmaceutical Ingredient (API) Intermediate for CNS Drugs

Pharmaceutical manufacturers incorporate this molecule as a key intermediate in the multi-step synthesis of certain central nervous system (CNS) drug candidates, notably NMDA receptor antagonists. The compound enters after the initial aromatic substitution stage and enables the specified cyclohexanol backbone formation required by advanced API structures. Downstream processes rely on strict documentation and batch traceability across every modification and purification step to support later regulatory submission. API producers adjust input levels according to target compound yield and impurity profile constraints dictated by the final registration dossier.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP EudraLex Volume 4 Part II
• US FDA 21 CFR Part 211
• Chinese Pharmacopoeia (ChP)

Typical usage ratio

• Ranges from 0.18 to 0.27 molar equivalents per target API batch, precision based on reaction pathway yield optimization and impurity control requirements.

Downstream process integration

• Charged as a secondary amine precursor during the key cyclization step, followed by extraction and purification prior to final API conversion.

Final product types

• Pharmaceutical-grade NMDA antagonists for CNS disorder therapies (e.g., depression adjuncts, neuroprotection candidates)

2. Intermediate for Analytical Reference Standards

Certified reference material producers employ this compound as a controlled precursor to prepare high-purity analytical standards required for method development and quality control within pharmaceutical R&D. The precursor supports calibration curve establishment and impurity profiling in regulated QC laboratories, requiring stringent documentation of source, handling, and purity. Lot-specific adjustment ensures traceability and performance validation for customer analytical systems. Downstream processing uses this compound in early-stage synthesis of reference molecules, focusing on minimizing carryover substances that could distort low-level detection checkpoints.

Industry compliance standards

• ISO 17034 General requirements for the competence of reference material producers
• USP General Chapter <11> (Reference Standards)
• OECD Principles of Good Laboratory Practice (GLP)
• FDA Guidance for Industry: Analytical Procedures and Methods Validation

Typical usage ratio

• 0.5–2.0% (w/w) in precursor batches; fine-tuned to match target concentration and response factor matching in solution preparation.

Downstream process integration

• Functions as the starting material for structural elucidation and chemical derivatization prior to reference standard isolation and certification.

Final product types

• Certified analytical reference standards for regulatory submission and laboratory QA/QC in pharmaceutical analysis

3. Synthesis of Research-Grade Chemical Probes

Specialty chemical suppliers engaged in supplying university and contract research markets leverage this material to synthesize labeled or structurally modified chemical probes targeting specific receptor or enzyme systems. These manufacturers integrate the compound mid-way through stepwise syntheses to achieve particular configuration or functional group orientation necessary for SAR (structure-activity relationship) studies. Input levels depend on probe design and desired detection limits in screening assays. Quality assurance teams monitor for trace impurities and conformance with academic or grant-led specifications.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• Good Laboratory Practice (GLP) where required for preclinical or toxicology research
• Material Safety Data Sheet (MSDS) and REACH registration for lab chemical supply compliance

Typical usage ratio

• 1.2–5.0% (w/w) in intermediate production runs; adjusted for target label incorporation efficiency and probe purity goals.

Downstream process integration

• Introduced in late-stage modifications as a backbone element for probe finalization prior to chromatographic purification and quality certification.

Final product types

• Research-grade chemical probes for life sciences, biochemistry, and pharmacological drug discovery

4. Precursor in Fine Chemical Contract Synthesis

Custom synthesis companies contract this compound as a dedicated building block for the production of small-volume, high-complexity molecular entities required by biotechnology developers or pilot projects. The hydrochloride form ensures controlled reactivity and batch reproducibility, reducing variability during process scale-up. Technicians tailor input according to project batch size, physicochemical parameters, and target molecule substitution patterns. Operations require detailed tracking from reception through final workup to conform with client-specific and regulatory expectations.

Industry compliance standards

• ISO 9001:2015 Quality management for custom synthesis
• REACH (EC 1907/2006) registration for chemical handling and use in the EU
• Client-specific confidentiality and audit agreements

Typical usage ratio

• 0.7–2.5 molar equivalents per target structure; tailored to molecular complexity, purification recoveries, and downstream transformation needs.

Downstream process integration

• Combined with functionalized halides or acid derivatives during carbon–carbon or carbon–heteroatom coupling steps prior to final compound identification and product isolation.

Final product types

• Innovative fine chemicals and specialty molecules for advanced materials research, pilot pharmaceutical development, or biotechnological innovation